CN116268416A - Composition containing maltodextrin and crystalline fructose and preparation method thereof - Google Patents

Composition containing maltodextrin and crystalline fructose and preparation method thereof Download PDF

Info

Publication number
CN116268416A
CN116268416A CN202310479411.2A CN202310479411A CN116268416A CN 116268416 A CN116268416 A CN 116268416A CN 202310479411 A CN202310479411 A CN 202310479411A CN 116268416 A CN116268416 A CN 116268416A
Authority
CN
China
Prior art keywords
composition
crystalline fructose
glucose
parts
carotene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310479411.2A
Other languages
Chinese (zh)
Inventor
范师振
范克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xizang Duoxin Health Technology Co ltd
Original Assignee
Xizang Duoxin Health Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xizang Duoxin Health Technology Co ltd filed Critical Xizang Duoxin Health Technology Co ltd
Priority to CN202310479411.2A priority Critical patent/CN116268416A/en
Publication of CN116268416A publication Critical patent/CN116268416A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/34—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a composition containing maltodextrin and crystalline fructose and a preparation method thereof, and relates to the field of medical formula foods. The composition has excellent efficacy, good safety and high stability, and can be used for preparing preoperative nutritional supplements so as to promote the sensitivity of the body to insulin and relieve postoperative insulin resistance.

Description

Composition containing maltodextrin and crystalline fructose and preparation method thereof
Technical Field
The invention relates to the field of medical formula foods, in particular to a composition containing maltodextrin and crystalline fructose and a preparation method thereof.
Background
Usually, patients need fasted fluid before selecting general anesthesia or local anesthesia, but carbohydrate loss in the patient after water forbidding is difficult to supplement, so that about 2 hours before operation, some nutritional compositions can be supplemented, thereby being beneficial to operation development and postoperative recovery. At present, modes of intravenous injection of 10% glucose and the like are commonly used, but generally, the compliance of patients in the method is poor, urine is increased due to too fast absorption, kidney burden is caused, and compared with the oral nutritional supplement, the oral nutritional supplement is higher in acceptance and more convenient.
Related studies, such as literature: li Rong, deng Fang use of a preoperative oral nutritional supplement in rapid rehabilitation therapy of colorectal cancer patients [ J ]. Colorectal anal surgery, 2019,25 (2): 5: in the rapid rehabilitation of patients with laparoscopic colon cancer radical surgery, the oral nutritional supplement for the patients before surgery can improve the immune function and the nutritional state of the patients, reduce the level of inflammatory factors and promote the recovery of intestinal functions after surgery. Furthermore, literature: zhou Yujing the effects of the intervention time of the oral nutritional supplement on postoperative complications and nutritional indexes of patients with thoracoscopic lung cancer [ J ]. International journal of protection, 2023,42 (02): 341-344. The study also shows that the oral nutritional supplement can effectively improve the nutritional status and immune function of patients with thoracoscopic lung cancer in the perioperative period, reduce the incidence rate of the complications of the patients, promote postoperative rehabilitation of the patients, and has better effect before operation.
Besides the literature, another patent CN107692221A discloses a nutritional supplement for patients to drink before surgery, which consists of water, sodium chloride, potassium chloride, glucose and an acidic pH regulator, and is characterized in that the proportion of the sodium chloride to the potassium chloride is (4-5): 1, the proportion of the glucose to the potassium chloride is (60-210): 1, and the content of the potassium chloride in the supplement is 0.2-0.4 g/L, thereby being beneficial to postoperative recovery and reducing the risk of surgery. And patent CN108835616a discloses a nutritional supplement for pre-operative consumption by patients consisting of only water, maltodextrin, fructose and pH regulator, which provides sufficient calories while having a low osmotic pressure, and which is safer for pre-operative, especially general anesthesia, patients without other additives than pH regulator.
From the above, the applicable surface of the preoperative nutritional supplement plays a key role in reducing postoperative complications, shortening recovery time and the like. However, up to now, the use of excessive amounts of some nutritional supplement additives causes safety hazards or there is a poor product stability, which in turn results in additional effects and even further increases safety risks. In response to such problems, it is necessary to find a nutritional supplement that is excellent in efficacy, safe and stable.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides a composition containing maltodextrin and crystalline fructose and a preparation method thereof, and the composition has excellent efficacy, good safety and high stability, and can be used for preparing a preoperative nutritional supplement so as to relieve postoperative insulin resistance.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the invention provides a composition, which comprises maltodextrin, crystalline fructose, glucose, ascorbyl palmitate, sugarcane polyphenol, isomalt and beta-carotene as raw materials.
Further, the composition comprises the following components in parts by weight: 60-90 parts of maltodextrin, 15-30 parts of crystalline fructose, 5-12 parts of glucose, 0.2-0.3 part of ascorbyl palmitate, 2-3 parts of sugarcane polyphenol, 0.1-0.2 part of isomalt and 0.1-0.3 part of beta-carotene.
Preferably, the composition comprises the following components in parts by weight: 80 parts of maltodextrin, 20 parts of crystalline fructose, 10 parts of glucose, 0.3 part of ascorbyl palmitate, 2.5 parts of sugarcane polyphenol, 0.2 part of isomalt and 0.2 part of beta-carotene.
Further, the weight ratio of the crystalline fructose to the glucose to the sugarcane polyphenol is 15-30:5-12:2-3. Preferably 20:10:2.5.
Further, the weight ratio of the ascorbyl palmitate to the isomalt to the beta-carotene is 0.2-0.3:0.1-0.2:0.1-0.3. Preferably 0.3:0.2:0.2.
Further, the invention provides a preparation method of the composition, which comprises the following steps: mixing maltodextrin, crystalline fructose, glucose, ascorbyl palmitate, sugarcane polyphenol, isomaltulose alcohol and beta-carotene.
Further, the composition provided by the invention can be used for preparing a preoperative nutritional supplement.
Further, the preoperative nutritional supplement also comprises water and other auxiliary materials which are suitable for being added in medical foods.
The invention has the technical effects that:
the product has excellent efficacy, good safety and high stability, wherein maltodextrin, crystalline fructose and glucose are used as carbohydrates and are easy to be absorbed by human bodies; the ascorbyl palmitate in the product has all the physiological activities of vitamin C, and the stability is higher; the sugarcane polyphenol can block active/passive transportation of glucose, control the rate of entering blood, reduce the blood sugar reaction after eating, and have corresponding regulation effect by matching with crystalline fructose; isomalt can adjust the taste of the nutritional agent, and has high stability, low energy and non-caries property; beta-carotene can be converted into vitamin A by human body according to the requirement, and has good antioxidation effect. Compared with additives added into other products, the product of the invention is safer and more stable, and according to research, the invention discovers that good interaction exists among crystalline fructose, glucose and sugarcane polyphenol and among ascorbyl palmitate, isomaltulose alcohol and beta-carotene, thus being capable of effectively controlling the absorption rate of the nutritional supplement, improving the sensitivity of the organism to insulin, relieving insulin resistance, improving the stability of the nutritional agent to a certain extent and prolonging the quality guarantee time; especially, the latter three materials can obtain better effect even in micro-adjustment.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and therefore the sources thereof are not particularly limited.
Examples 1 to 3 and comparative examples 1 to 5
Table 1 example formulation (Unit: parts by weight)
Raw materials Example 1 Example 2 Example 3
Maltodextrin 60 90 80
Crystalline fructose 15 30 20
Glucose 5 12 10
Ascorbyl palmitate 0.2 0.3 0.3
Sugarcane polyphenol 2 3 2.5
Isomalt 0.1 0.2 0.2
Beta-carotene 0.1 0.3 0.2
Table 2 comparative example formulation (Unit: parts by weight)
Figure BDA0004206569070000041
The preparation method of the compositions of examples 1-3 and comparative example 1 comprises the following steps: mixing maltodextrin, crystalline fructose, glucose, ascorbyl palmitate, sugarcane polyphenol, isomaltulose alcohol and beta-carotene. The compositions of comparative examples 2-5 were prepared without the addition of the corresponding starting materials.
1. Stability acceleration test
The test method comprises the following steps: the products in each example are placed for 3 months under the conditions that the temperature is 40 ℃ and the humidity is 75%, three indexes of crystalline fructose and ascorbyl palmitate are selected, the change condition of each index before and after the test is examined, and the initial detection result is taken as 100% reference.
TABLE 3 stability acceleration test results
Examples Crystalline fructose (%) Ascorbyl palmitate (%)
Example 1 100.6 91.3
Example 2 99.8 93.5
Example 3 100.2 96.7
Comparative example 1 84.4 68.1
Comparative example 2 90.3 64.2
Comparative example 3 85.0 58.0
Comparative example 4 73.9 36.3
Comparative example 5 87.2 60.5
According to the table, the product provided by the invention has good stability, and can effectively promote the stability among various components. In contrast, when the formulation was adjusted, the crystalline fructose or ascorbyl palmitate had reduced component content after the accelerated stability test.
2. Effect of the compositions of the present invention on post-operative insulin resistance
Test animals: SD rats total 80, male, weight 220-240g;
the test method comprises the following steps: randomly dividing rats into 10 groups, wherein 8 rats in each group are not treated, performing abdominal operation after the rest rats are anesthetized by intraperitoneal injection of 1% pentobarbital sodium solution, and suturing after 5cm and 5min of a median incision in the abdomen; one group of rats subjected to abdominal operation was selected as a control group, the rats of the group were not preoperatively perfused with the composition of the present invention, and the remaining rats of the group subjected to abdominal operation were preoperatively perfused with the composition (5 mL, mass fraction: 10%) in each example of stomach for 1h, and 5 μl of peripheral blood samples were collected for 5h before and 1h after each operation to detect fasting blood glucose and fasting insulin content, while calculating insulin resistance index: insulin resistance index = fasting insulin x fasting blood glucose/22.5.
TABLE 4 fasting blood glucose and fasting insulin conditions
Figure BDA0004206569070000051
Figure BDA0004206569070000061
( And (3) injection: * : intra-group postoperative pre-operative comparison, p < 0.05,: comparing intra-group postoperative with preoperative comparison, wherein p is less than 0.01; #: comparing the group with the control group, p < 0.05, # #: p < 0.01 compared with the control group. )
TABLE 5 insulin resistance test results
Figure BDA0004206569070000062
( And (3) injection: * : intra-group postoperative pre-operative comparison, p < 0.05,: comparing intra-group postoperative with preoperative comparison, wherein p is less than 0.01; #: comparing the group with the control group, p < 0.05, # #: p < 0.01 compared with the control group. )
As is clear from the above table, the operation causes the body to undergo catabolic reaction and at the same time insulin resistance to increase, but the efficiency of insulin to promote the uptake and utilization of glucose and the like is lowered, thereby causing insulin resistance. The composition can effectively regulate insulin so as to stabilize blood sugar, and the insulin resistance index between groups and in groups is reduced; the composition in comparative example 1 was not remarkable in the regulation effect on insulin and the like due to unreasonable formulation matching, and the increment of blood sugar was also large, and the composition in the remaining comparative examples was weaker in the whole than the formulation of the present application, although having the corresponding regulation effect.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.

Claims (10)

1. A composition characterized by: the raw materials comprise maltodextrin, crystalline fructose, glucose, ascorbyl palmitate, sugarcane polyphenol, isomaltulose and beta-carotene.
2. The composition of claim 1, wherein: the weight portion of the composition comprises: 60-90 parts of maltodextrin, 15-30 parts of crystalline fructose, 5-12 parts of glucose, 0.2-0.3 part of ascorbyl palmitate, 2-3 parts of sugarcane polyphenol, 0.1-0.2 part of isomalt and 0.1-0.3 part of beta-carotene.
3. The composition of claim 2, wherein: the weight portion of the composition comprises: 80 parts of maltodextrin, 20 parts of crystalline fructose, 10 parts of glucose, 0.3 part of ascorbyl palmitate, 2.5 parts of sugarcane polyphenol, 0.2 part of isomalt and 0.2 part of beta-carotene.
4. The composition of claim 1, wherein: the weight ratio of the crystalline fructose to the glucose to the sugarcane polyphenol is 15-30:5-12:2-3.
5. The composition of claim 4, wherein: the weight ratio of the crystalline fructose to the glucose to the sugarcane polyphenol is 20:10:2.5.
6. The composition of claim 1, wherein: the weight ratio of the ascorbyl palmitate to the isomalt to the beta-carotene is 0.2-0.3:0.1-0.2:0.1-0.3.
7. The composition of claim 6, wherein: the weight ratio of the ascorbyl palmitate to the isomalt to the beta-carotene is 0.3:0.2:0.2.
8. A method of preparing a composition according to any one of claims 1 to 7, wherein: the method comprises the following steps: mixing maltodextrin, crystalline fructose, glucose, ascorbyl palmitate, sugarcane polyphenol, isomaltulose alcohol and beta-carotene.
9. Use of a composition according to any one of claims 1-7 for the preparation of a pre-operative nutritional supplement.
10. A preoperative nutritional supplement characterized by: comprising the composition of any one of claims 1-7.
CN202310479411.2A 2023-04-28 2023-04-28 Composition containing maltodextrin and crystalline fructose and preparation method thereof Pending CN116268416A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310479411.2A CN116268416A (en) 2023-04-28 2023-04-28 Composition containing maltodextrin and crystalline fructose and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310479411.2A CN116268416A (en) 2023-04-28 2023-04-28 Composition containing maltodextrin and crystalline fructose and preparation method thereof

Publications (1)

Publication Number Publication Date
CN116268416A true CN116268416A (en) 2023-06-23

Family

ID=86783611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310479411.2A Pending CN116268416A (en) 2023-04-28 2023-04-28 Composition containing maltodextrin and crystalline fructose and preparation method thereof

Country Status (1)

Country Link
CN (1) CN116268416A (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355695A (en) * 1999-04-14 2002-06-26 利库德天然产品工业有限公司 Compounds useful in reducing level of insulin like growth factor-I (IGF-I) in blood
CN104957602A (en) * 2015-05-22 2015-10-07 长沙普源生物科技有限公司 Sugarcane bioactive component composition, functional health food, and preparation method of sugarcane bioactive component composition and functional health food
CN107927515A (en) * 2017-11-03 2018-04-20 河北健素临床营养有限公司 For preoperative and postoperative solid beverage and drink
CN108142951A (en) * 2018-01-31 2018-06-12 广州纽健生物科技有限公司 Improve nutraceutical of postoperative insulin resistance and its preparation method and application
CN110638048A (en) * 2019-10-30 2020-01-03 山东若尧特医食品有限公司 Electrolyte formula powder and preparation method thereof
CN111067101A (en) * 2019-12-17 2020-04-28 浙江禾健生营养科技有限公司 Electrolyte formula powder for nutritional supplement of preoperative patients and preparation method thereof
CN111165825A (en) * 2019-07-17 2020-05-19 江苏西宏生物医药有限公司 Pre-operative enteral nutritional composition
US20220193156A1 (en) * 2020-12-23 2022-06-23 Thi Tuyet Mai Ta Preoperative compositions and methods of preparation thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355695A (en) * 1999-04-14 2002-06-26 利库德天然产品工业有限公司 Compounds useful in reducing level of insulin like growth factor-I (IGF-I) in blood
CN104957602A (en) * 2015-05-22 2015-10-07 长沙普源生物科技有限公司 Sugarcane bioactive component composition, functional health food, and preparation method of sugarcane bioactive component composition and functional health food
CN107927515A (en) * 2017-11-03 2018-04-20 河北健素临床营养有限公司 For preoperative and postoperative solid beverage and drink
CN108142951A (en) * 2018-01-31 2018-06-12 广州纽健生物科技有限公司 Improve nutraceutical of postoperative insulin resistance and its preparation method and application
CN111165825A (en) * 2019-07-17 2020-05-19 江苏西宏生物医药有限公司 Pre-operative enteral nutritional composition
CN110638048A (en) * 2019-10-30 2020-01-03 山东若尧特医食品有限公司 Electrolyte formula powder and preparation method thereof
CN111067101A (en) * 2019-12-17 2020-04-28 浙江禾健生营养科技有限公司 Electrolyte formula powder for nutritional supplement of preoperative patients and preparation method thereof
US20220193156A1 (en) * 2020-12-23 2022-06-23 Thi Tuyet Mai Ta Preoperative compositions and methods of preparation thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘奕博;任国谱;: "抗坏血酸及抗坏血酸棕榈酸酯的稳定性研究", 食品工业科技, vol. 33, no. 23, pages 303 - 305 *
姜典镇;: "液态奶中麦芽糊精的检测探讨", 河南预防医学杂志, vol. 16, no. 06, 25 December 2005 (2005-12-25), pages 336 - 337 *
尤新;: "异麦芽酮糖的功能与应用", 食品安全导刊, no. 15, pages 62 - 63 *
江咏梅;郭志丽;李玲芳;: "镁和β-胡萝卜素对2型糖尿病大鼠胰岛素抵抗及抗氧化能力影响的研究", 中国实验诊断学, vol. 13, no. 06, pages 735 - 738 *

Similar Documents

Publication Publication Date Title
JP2643669B2 (en) Algin-containing foods
Akazome Characteristics and physiological functions of polyphenols from apples
US20090004326A1 (en) Beverage Additive and Method of Making the Same
CN1650731A (en) Corn peptide beverage and its processing method
JP2006502103A (en) Condensed palatinose and method for producing the same
CN111165825A (en) Pre-operative enteral nutritional composition
CN113575694A (en) Low-fat modified milk powder containing composition for assisting in reducing blood fat and lowering blood pressure
CN112715957A (en) Biological small molecular peptide composition for dispelling effects of alcohol and protecting liver and preparation method thereof
US4629725A (en) Method for inhibiting increase in blood sugar content
CN116268416A (en) Composition containing maltodextrin and crystalline fructose and preparation method thereof
KR100900875B1 (en) Composition for preventing and treating diabetes comprising the extract of gang-hwa mugwort
KR20200016608A (en) The health food composition for regulating weight
CN114668106B (en) Folic acid and calcium composite anti-retrogradation recombinant rice and preparation method thereof
DE60013560T2 (en) MALTO OLIGOSACCHARIDE DERIVATIVES AND ITS APPLICATIONS
CN107173445B (en) Enteral nutrition preparation with balanced nutrition
CN112566514A (en) Composition for promoting uric acid excretion, composition for inhibiting URAT1, and composition for lowering uric acid level in blood
CN113440514A (en) Composition containing hesperetin and application thereof in synergistic blood sugar reduction
CN113693231A (en) A nutritional dietary composition for radiotherapy and chemotherapy of tumor, and its preparation method
CN108379455B (en) Uric acid reducing composition
CN107048219A (en) Increase composition of bone density and preparation method thereof
CN113545479A (en) Formula food and application thereof
KR20130073211A (en) The food composition for patients containing dietary fiber
CN115251372B (en) Food suitable for non-dialysis nephrosis patient and preparation method thereof
CN113546074B (en) Composition containing 3-O-methyl quercetin and application thereof in alpha-glucosidase inhibition
KR100266799B1 (en) Nutritional formula for patients with renal disease and process for preparing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination